Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Perelman School of Medicine at the University of Pennsylvania Advanced Search

Nevena Damjanov, MD

Nevena Damjanov, MD

faculty photo
Professor of Clinical Medicine
Department: Medicine

Contact information
Penn Presbyterian Medical Center
51 North 39th Street
103A MAB
Philadelphia, PA 19104
Office: 215-662-8488
Fax: 215-243-3249
Education:
BA (Biology, Philosophy)
University of Pennsylvania, 1985.
MD (Internal Medicine)
Hahnemann University, 1989.
CTF (Leading Success)
Raymond and Ruth Perelman School of Medicine University of Pennsylvania, 2015.
Permanent link
 
Perelman School of Medicine > Faculty > Search

Selected Publications

V. Mazzaferro, B. El-Rayes, C. Cotsoglou, W. P. Harris, N. Damjanov, G. Masi, L. Rimassa, N. Personeni, F. Braiteh, V. Zagonel, K.P. Papadopoulos, T. Hall, Y. Wang, G. Abbadessa, B. Schwart, J. Kazakin, M. Droz Dit Busset, W. Shaib: ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations. J Clin Oncol 35, June 2017 Notes: Poster Discussion Presentation.

Mark H. O'Hara, Thomas Benjamin Karasic, Irina Vasilevskaya, Maryann Redlinger, Arturo Loaiza-Bonilla, Ursina R. Teitelbaum, Bruce J. Giantonio, Nevena Damjanov, Kim Anna Reiss, Mark Alan Rosen, Daniel F Heitjan, Andrea B. Troxel, Ravi K. Amaravadi, Peter J. O'Dwyer: Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer J Clin Oncol 35, June 2017.

Lorenza Rimassa, Eric Assenat, Markus Peck-Radosavljevic, Vittorina Zagonel, Marc Pracht, Elena Rota-Caremoli, Philippe Mathurin, William Harris, Luigi Bolondi, Maria Reig, Nevena Damjanov, Bruno Daniele, Camillo Porta, Vincenzo Mazzaferro, Giovanni Abbadessa, Brian Schwartz, Maria Lamar, Terri Goldberg, Armando Santoro, Jordi Bruix: Second-Line Tivantinib (ARQ 197) vs Placebo in Patients (Pts) with MET-High Hepatocellular Carcinoma (HCC): Results of the METIV-HCC Phase 3 Trial. J Clin Oncol 35, June 2017 Notes: Oral Presentation.

Braxton DR, Saxe D, Damjanov N, Stashek K, Shroff S, Morrissette JD, Tondon R, Furth EE.: Molecular and cytogenomic profiling of hepatic adenocarcinoma expressing inhibinA, a mimicker of neuroendocrine tumors: proposal to reclassify as "cholangioblastic variant of intrahepatic cholangiocarcinoma". Hum Pathol 62: 232-241, April 2017.

Rimassa, L., Reig, M., Abbadessa, G., Peck-Radosavljevic, M., Harris, W., Zagonel, V., Pastorelli, D., Rota Caremoli, E., Porta, C.,Damjanov, N., Patel, H., Daniele, B., Lamar, M., Schwartz, B., Goldberg, T., Santoro, A., Bruix, J.: Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma World J Gastroenterol 23(13): 2448-2452, April 2017.

Jacob E. Shabason, Jerry Chen, Smith Apisarnthanarax, Nevena Damjanov, Bruce Giantonio, Arturo Loaiza-Bonilla, Peter O’Dwyer, Mark O’Hara, Kim Reiss, Ursina Teitelbaum, Paul Wissel, Jeffery Drebin, Charles Vollmer, Michael Kochman, Rosemarie Mick, Norge Vergara, Nirag Jhala, Abigail Berman, Jay Dorsey, Sydney M. Evans, Gary Kao, John. N. Lukens, John P. Plastaras, James M. Metz, Edgar Ben-Josef: A Phase I Dose Escalation Trial of Nab-Paclitaxel and Fixed Dose Radiation in Patients with Unresectable or Borderline Resectable Pancreatic Cancer Association for Clinical and Translational Science Annual Meeting April 2017.

Brown,J.C., Troxel, A.B., Ky, B., Damjanov, N., Zemel, B.S., Rickels, M.R., Rhim, A.D., Rustgi, A.K., Courneya, K.S., Schmitz, K.H.: A randomized phase II dose–response exercise trial among Colon Cancer Survivors: Purpose, Study Design, methods, and recruitment results, Contemporary Clinical Trials 47: 366–375, March 2016.

Lea Lowenfeld MD, Jashodeep Datta MD, Russell S. Lewis Jr., Matthew T. McMillan, Ronac Mamtani MD, Nevena Damjanov MD, Vinay Chandrasakhara MD, Giorgos Karakousis MD, Jeffrey Drebin MD PhD, Douglas Fraker MD, Robert E. Roses MD: Multimodality Treatment of T4 Gastric Cancer in the United States: Utilization Trends and Impact on Survival. Annals of Surgical Oncology 22(Suppl 3): S863-72, December 2015.

Vassallo,R; Prechtel-Dunphy,E; Damjanov,N; Tsikouras,A; Favatella,J; Kasbekar,N.: Impact of Comprehensive Pharmacy Services on Patient Centered Outcomes in an Oncology Clinic. UHC Pharmacy Council Meeting: New Orleans, LA December 2015 Notes: "Poster Presentation"

E.M. Egert, R.D. Johnson, M.M. Watts, J. Booty, N. Damjanov, R. Mohr, M. Lee, N.S. Mungiole, D.E. Kaplan, J. Griffiths, H.A. Shaikh, R.C. Hawley, M.S. Ghosh: A Regional Multidisciplinary Liver Tumor Board improves Access to Hepatocellular Carcinoma Treatment for Patients Geographically Distant from Tertiary Medical Center. AASLD, The Liver Meeting 2015(521), November 2015 Notes: "Poster Presentation"

back to top
Last updated: 05/07/2017
The Trustees of the University of Pennsylvania